Last reviewed · How we verify
AZD2281
PARP inhibitor
PARP inhibitor Used for Ovarian cancer, Breast cancer.
At a glance
| Generic name | AZD2281 |
|---|---|
| Also known as | Olaparib, Olaparib; Lynparza, Olaparib, Lynparza |
| Sponsor | AstraZeneca |
| Drug class | PARP inhibitor |
| Target | PARP |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
AZD2281 is a potent inhibitor of poly (ADP-ribose) polymerase (PARP) enzymes, which play a key role in DNA repair. By inhibiting PARP, AZD2281 can induce synthetic lethality in cancer cells with defects in homologous recombination repair (HRR).
Approved indications
- Ovarian cancer
- Breast cancer
Common side effects
- Nausea
- Fatigue
- Vomiting
Key clinical trials
- A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032) (PHASE3)
- A Study to Assess Change in Disease Activity and Adverse Events in Adult Participants With Gynecologic Cancers Receiving Intravenous Infusion of IMGN151 as Monotherapy or in Combination With Other Therapies (PHASE2)
- Testing the Combination of DS-8201a and Olaparib in HER2-Expressing Cancers With Expansion in Patients With Platinum Resistant Ovarian Cancer (PHASE1)
- Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial (PHASE2)
- Testing Two Oral Drugs Combination (Cediranib and Olaparib) Compared to a Single Drug (Olaparib) for Men With Advanced Prostate Cancer (PHASE2)
- Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR) (PHASE2)
- Testing the Addition of Pembrolizumab, an Immunotherapy Cancer Drug to Olaparib Alone as Therapy for Patients With Pancreatic Cancer That Has Spread With Inherited BRCA Mutations (PHASE2)
- APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- AZD2281 CI brief — competitive landscape report
- AZD2281 updates RSS · CI watch RSS
- AstraZeneca portfolio CI